Roche Xeloda
Executive Summary
sNDA will be submitted week of Sept. 13 for capecitabine as first-line treatment of metastatic colorectal cancer, Roche said. Xeloda is currently approved for the treatment of patients with metastatic breast cancer who have not responded to or who are no longer responding to chemotherapy with both paclitaxel (Bristol's Taxol) and an anthracycline-containing regimen